D
Derm Effects | London, Canada
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
PF-04965842
ESK-001
Curious how this site stacks up to its peers?
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
3 of 3 total trials
The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with prurigo nodularis.
Enrolling
Prurigo Nodularis
Other: Matching Placebo
Biological: barzolvolimab
The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to...
Enrolling
Psoriasis
Severe Psoriasis
Drug: Open-Label ESK-001
Drug: Blinded ESK-001
B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...
Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg
Trial sponsors
A
Clinical trials
Research sites
Resources
Legal
© Copyright 2025 Veeva Systems